The Everstone Group makes a strategic investment in CPC Diagnostics, advised by 7i Capital Advisors
The Everstone Group, via its healthcare platform Everlife, has made a strategic investment in CPC Diagnostics Pvt. Ltd.
Everstone Group (“Everstone”), through its pan-Asia healthcare platform Everlife, has marked its prominent presence in the Indian market through a strategic investment in leading Indian in vitro diagnostic (“IVD”) products company CPC Diagnostics Pvt Ltd (“CPC”).
7i Capital Advisors acted as the exclusive sell-side advisor on this transaction.
Dr. Arjun Oberoi, Vice Chairman, Everlife and Managing Director, Everstone Capital stated: “We are delighted to invest in CPC Diagnostics and help scale up its presence across the diagnostics sector. Its strong manufacturing and R&D capabilities make them an ideal partner for us, and we will help them expand in markets beyond India. Everlife can also leverage on CPC to grow its value segment range of products, to cater to the growing demand of quality medical devices within emerging markets.”
“Everlife has an established presence in the Southeast Asian market and vision to create a leading pan-Asia platform. It also provides a unique combination of financial strength as well as strong domain expertise in the healthcare space in Asia. It is our privilege to become part of this platform. We believe that this strategic partnership will assist CPC in reaching out to newer customers and markets for its product portfolio, in addition to the other important strategic benefits which can be derived by being associated with the well-renowned Everstone group”, said Mr. R Kailasnath, Managing Director, CPC Diagnostics Pvt. Ltd.
“This association will be a key milestone in the Indian IVD industry. Both Everlife and CPC bring in complementary skill sets in terms of domain expertise and capabilities to build a strong sustainable platform in the IVD space which will be leader in both the Indian and pan-Asian markets.” said Mr. Manoj Patkar, Executive Director and Partner, 7i Capital Advisors.
Everlife Asia is a buy-and-build platform aimed to provide complete solutions for the healthcare and research industries in Southeast Asia and India. As part of the Everstone Group, Everlife invests in manufacturers and distributors in the region covering key strategic segments including in-vitro diagnostics, medical diagnostics, critical care equipment, implants and consumables. Cure Capital is a minority investor in Everlife. Everlife’s portfolio companies represent more than 200 principals, and its more than 600 employees operate in 7 countries. For more information, visit www.everlifeasia.com
About Everstone Group
Everstone is a premier investment group focused on India and Southeast Asia, with assets in excess of US$5 billion across private equity, real estate, green infrastructure and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India (Mumbai, Delhi, Bangalore), London, New York and Mauritius, comprising best-of-breed investing, operations and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com
About CPC Diagnostics
CPC is a Chennai based manufacturer and marketer of in-vitro diagnostic products. CPC has three decades of experience in the industry and is well known for its pioneering efforts in introduction of new products and technologies. With dedicated marketing sales and service teams, CPC operates in India, Sri Lanka and Bangladesh. For more information, please visit www.cpcdiagnostics.in